| This CME activity was made possible by an educational grant from |  |
|
||||
|
This CME activity is endorsed by the American Academy of Addiction Psychiatry.
Jointly sponsored by the University of Medicine & Dentistry of New Jersey (UMDNJ)–Center for Continuing & Outreach Education and Precept Education Sciences.
|
 |
INTRODUCTION AMA PRA Category 1 Credit™ for completing this enduring material. Please note that the course is accredited only for physicians (MD, DO, or equivalent). All other participants receive a certificate of completion. Using an interactive audio/slide/video format, the presentations include question-and-answer sessions and explore the following topics:
Learning Objectives Upon completion of this course, participants should be able to
Accreditation and Credit Designation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of UMDNJ–Center for Continuing and Outreach Education and Precept Educational Sciences. UMDNJ–Center for Continuing and Outreach Education is accredited by the ACCME to provide continuing medical education for physicians. UMDNJ–Center for Continuing and Outreach Education designates this educational activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. All participants are required to view the presentations in their entirety, pass the course test, and complete an evaluation form before receiving their continuing education certificates (via email and/or PDF download). No fees are charged to participate in the program or to receive the certificate. This activity was reviewed for relevance, accuracy of content, balance of presentation, and time required for participation by Douglas M. Ziedonis, MD, MPH; Mark Miceli, MD; and John F. Schultz, MD, PhD. Faculty Disclosures and Biographies ACCME and UMDNJ–Center for Continuing and Outreach Education require that the faculty participating in a continuing medical education activity disclose to participants any significant financial interest or other relationship (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. This CME activity includes discussions regarding the use of medications that are outside of the approved labeling for these products. Physicians should consult the current prescribing information for these products. Kathleen T. Brady, MD, PhD Kathleen T. Brady, MD, PhD, received her medical degree from the Medical University of South Carolina (MUSC) and her postdoctoral degree in pharmacology from the Medical College of Virginia. While at MUSC, she also completed a residency in psychiatry, served as chief resident, and completed a fellowship in addiction psychiatry. Dr Brady is a board-certified psychiatrist specializing in addiction psychiatry. As a professor of psychiatry at MUSC, Dr Brady acts as director of the Women's Research Center, associate director of the Neuroscience Institute, associate director of the General Clinical Research Center, director of the Addiction Psychiatry Fellowship Program at the Center for Drug and Alcohol Programs, and director of the South Carolina Node for the Clinical Trials Network of the National Institute on Drug Abuse (NIDA). Dr Brady's research interests are in the areas of drug and alcohol abuse/addiction, as well as comorbid conditions such as posttraumatic stress disorder and other anxiety disorders. Dr Brady has been very active in organizations addressing the concerns of psychiatry and addictions. She has served as principal investigator, co-principal investigator, and mentor on numerous research projects and is past president of the Association for Medical Education and Research in Substance Abuse. Dr Brady has served on the Scientific Advisory Council of the NIDA and the Committee on Community-Based Treatment of the Institute of Medicine, National Academy of Science, as well as the Board of Directors of the College of Problems of Drug Dependence. She is also the president of the American Academy of Addiction Psychiatry. Dr Brady is associate editor and book review editor for the journal Substance Abuse and is a reviewer for, and has served on, the editorial boards of several peer-reviewed journals. She has received awards for her research, teaching, and clinical work and has been listed in Best Doctors in America since 1998. Furthermore, she has published more than 300 articles, abstracts, and book chapters and has been an invited speaker at medical meetings, grand rounds, and symposia throughout the country. Richard N. Rosenthal, MD Richard N. Rosenthal, MD, received his medical degree from the State University of New York, Downstate Medical Center. He then completed a rotating internship and a residency in psychiatry in 1984 at the Mount Sinai Medical Center in New York City, where he was chief resident. He is currently a professor of clinical psychiatry at Columbia University and chairman of psychiatry at St. Luke's–Roosevelt Hospital Center. He is also immediate past president of the American Academy of Addiction Psychiatry, a distinguished fellow of the American Psychiatric Association, and a fellow of the New York Academy of Medicine. He is a diplomate of the American Board of Psychiatry and Neurology in psychiatry, with subspecialty certification in addiction psychiatry. Prior to coming to St. Luke's–Roosevelt, he was associate chairman for clinical services of the Beth Israel Medical Center (BIMC), New York, Department of Psychiatry, and director of the Division of Substance Abuse at Albert Einstein College of Medicine. Following residency training, he served first as unit chief and then division chief of the Substance Abuse Service (Psychiatry) at BIMC. During this time, he created the Combined Psychiatric and Addictive Disorders Treatment Research Program, and codeveloped and manualized brief supportive psychotherapy for Beth Israel's Brief Psychotherapy Research Program. Dr Rosenthal's main research focus has been on the evaluation and treatment of the severely mentally ill with co-occurring addictive disorders, and he has been a clinical, research, and program development consultant to hospitals and state and federal agencies. He also has a long-term interest in medical informatics and is on the steering committee of the American Association for Technology in Psychiatry, as well as the Information Systems Review Committee of the New York State Hospital Planning and Review Council. In 2004, Governor Pataki appointed Dr Rosenthal to the New York State Mental Health Services Council. Dr Rosenthal has received numerous awards and honors, including New York Magazine's Best Doctors in New York in 1998-2005. Most recently, he was appointed as a senior fellow, SAMHSA Co-Occurring Disorders Center for Excellence and co-chairman of its National Steering Council. He has authored 50 peer-reviewed journal articles, book chapters, and books. He maintains a private practice of psychotherapy and psychopharmacology for mood and addictive disorders. Douglas M. Ziedonis, MD, MPH Douglas M. Ziedonis, MD, MPH, is a professor of psychiatry at the UMDNJ–Robert Wood Johnson Medical School and a professor in health systems and policy at the UMDNJ–School of Public Health. He is the director of the Division of Addiction Psychiatry and visiting professor at the Rutgers University Center of Alcohol Studies. Dr Ziedonis is the recipient of numerous awards and grants from the National Institute of Mental Health, National Institute of Drug Abuse, Center for Substance Abuse Treatment, Robert Wood Johnson Foundation, and other agencies. He has written more than 100 articles and other publications and has been a consultant for the Center for Substance Abuse Treatment and the National Institute of Drug Abuse on the topics of medication development and implementing new treatments into clinical practice. Additionally, he has served on the American Psychiatric Association's Council on Addictions and helped develop practice guidelines on substance use disorders. Reviewer Disclosures Mark Miceli, MD Sources of Funding for Research: None. John F. Schultz, MD, PhD Sources of Funding for Research: None. Instructions to Participants Course participants will view audio/slide/video presentations and then must successfully complete a test in order to receive continuing medical education credit. Full instructions are available on the user instructions page. Disclaimer The opinions expressed herein are those of the faculty and do not necessarily represent the views of the sponsors, accrediting body, commercial supporter, or publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects, before administering pharmacologic therapy to patients. Medicine is a constantly changing science, and clearly established therapies are not always available for every condition. New research findings necessitate continual changes in drug and treatment therapies. Reasonable efforts have been made to provide up-to-date, accurate information that is within generally accepted medical standards at the time of publication. However, as medical science is ever evolving, and human error is always possible, the sponsors, accrediting body, commercial supporter, and publisher (or any other involved party) do not guarantee total accuracy or comprehensiveness of the information in this article, and they are not responsible for omissions or errors or the results of using information provided in this course. The participant should confirm the accuracy of the information in this activity from other sources. In particular, all drug doses, indications, and contraindications should be confirmed in package inserts. Click here to view minimum system requirements.
|
